Advertisement
Canada markets open in 1 hour 31 minutes

  • S&P/TSX

    21,516.90
    -94.40 (-0.44%)
     

  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     

  • DOW

    38,834.86
    +56.76 (+0.15%)
     

  • CAD/USD

    0.7292
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    81.68
    +0.11 (+0.13%)
     

  • Bitcoin CAD

    90,759.52
    +1,366.22 (+1.53%)
     

  • CMC Crypto 200

    1,376.81
    -5.85 (-0.42%)
     

  • GOLD FUTURES

    2,353.20
    +6.30 (+0.27%)
     

  • RUSSELL 2000

    2,025.23
    +3.22 (+0.16%)
     

  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     

  • NASDAQ futures

    20,033.25
    +114.00 (+0.57%)
     

  • VOLATILITY

    12.58
    +0.10 (+0.80%)
     

  • FTSE

    8,235.25
    +30.14 (+0.37%)
     

  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     

  • CAD/EUR

    0.6801
    +0.0014 (+0.21%)
     

Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference

Ardelyx, Inc.
·1 min read
Ardelyx, Inc.
Ardelyx, Inc.

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time in New York City.

To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.

About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com